UltraSight raises $24 million to expand AI-guided cardiac imaging

UltraSight closed a $24 million Series B2 round to grow its U.S. commercial footprint and develop new cardiac workflows for intensive care and circulatory support settings. The company says the funding comes as its FDA-cleared Echosystem platform gains clinical evidence and more than 10 commercial deployments.

Why it matters: - UltraSight is trying to widen access to diagnostic-quality cardiac ultrasound in settings where trained sonographers are scarce. - The new capital is meant to speed U.S. adoption of the Echosystem and extend AI-guided imaging into time-critical care areas. - The company is also betting that broader workflow support can help health systems make faster imaging decisions at the point of care.

What happened: - UltraSight raised $24 million in Series B2 financing. - The round was led by Alive HealthTech Growth Fund. - Deep Insight, Star51 Capital, Connecticut Innovations and eHealth Ventures also participated. - Existing investors Mayo Clinic Ventures, NYU and Iron Nation joined the round. - The company said the financing will support commercial expansion in the United States. - UltraSight said the proceeds will also fund new workflows for intensive care unit and circulatory support settings. - The company announced the financing in Boston on Sept. 23, 2026.

The details: - UltraSight's Echosystem is deployed across more than 10 commercial sites in intensive care settings. - The platform combines structured training, real-time AI guidance and analytics for focused echocardiography exams under physician oversight. - UltraSight says its software has FDA 510(k) clearance to assist medical professionals in performing cardiac ultrasound scans. - The company said it continues to generate clinical evidence that trained non-sonographer clinicians can acquire diagnostic-quality cardiac images with AI guidance. - A study published in JAMA Cardiology found novice operators using AI-guided cardiac ultrasound could acquire high-quality images for automated detection of moderate or greater aortic stenosis, with 93% sensitivity and 96% specificity. - The study supports the potential for AI-guided ultrasound to expand access to cardiac screening and earlier patient evaluation. - UltraSight said the financing will also support strategic collaborations to expand adoption of the Echosystem product line. - The company said the Echosystem integrates proprietary AI innovations across time-critical cardiac care pathways.

Between the lines: - The round combines health-tech investors, strategic backers and current shareholders, which suggests UltraSight is positioning both for commercial growth and clinical credibility. - The focus on ICU and circulatory support workflows points to a push beyond screening into higher-acuity care where speed matters. - The JAMA Cardiology data gives the company a stronger evidence base as it pitches health systems on workflow automation and access gains. - Rick Geoffrion, the newly appointed chairman of UltraSight's board, brings more than 30 years of cardiovascular device experience across interventional cardiology, circulatory support, structural heart and commercialization. - UltraSight added Dudi Klein, Tal Wenderow and Barak Ben-Eliezer to its board, bringing additional healthcare, medtech and commercialization experience.

What's next: - UltraSight plans to use the financing to expand U.S. sales and partnerships. - The company will develop additional high-value workflows for critical care and circulatory support use cases. - UltraSight is expected to keep building evidence for AI-guided image acquisition as it seeks broader adoption across cardiovascular care.

The bottom line: - UltraSight is using fresh funding, clinical data and board expansion to push its AI-guided cardiac workflow platform from early traction into broader hospital adoption. - More information